Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme. From a phase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 pa...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Roboz, Gail J., DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Mims, Alice S., Prince, Gabrielle T., Altman, Jessica K., Arellano, Martha L., Donnellan, Will, Erba, Harry P., Mannis, Gabriel N., Pollyea, Daniel A., Stein, Anthony S., Uy, Geoffrey L., Watts, Justin M., Fathi, Amir T., Kantarjian, Hagop M., Tallman, Martin S., Choe, Sung, Dai, David, Fan, Bin, Wang, Hongfang, Zhang, Vickie, Yen, Katharine E., Kapsalis, Stephanie M., Hickman, Denice, Liu, Hua, Agresta, Samuel V., Wu, Bin, Attar, Eyal C., Stone, Richard M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Plenary Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019193/
https://ncbi.nlm.nih.gov/pubmed/31841594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019002140
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi